EPIMMUN® turbo - by skin-resident DC targeting vaccine
The combination of EPIMMUN® epidermal immunization via lasermicroporation with a skin-resident DC targeting vaccine formulation shapes and potentiates immune responses.
A STRONGER IMMUNE RESPONSE
The delivery of immunogens to relevant cells in targeted skin layers induces a strong immune response.
A study with the objective of targeting dermal cross presenting CD8a type DCs for delivering antigen as immunotherapy treatment against melanoma in mice5 showed that Xcl1 specific fusion proteins bound specifically to the dermal cross presenting DCs after the process of laser microporation.
Results of skin vaccination using targeted Bet mannan nanoparticles in a mouse model showed that coupling of Bet v1 to mannan boosts its immunogenicity more when delivered epicutaneously than intradermally7 (see data on the right).
"Our work shows that mannan conjugation is an efficient mechanism to generate safer and highly immunogenic allergy vaccines. In addition, we showed that a potent vaccine results from the combination of targeting the antigen to specialized DC populations and optimal activation of these DCs rather than increased delivery to lymphoid organs. Finally, mannan conjugation combined with epicutaneous immunization induces potent IgE-blocking antibodies and non-TH2 responses against Bet v 1, both mechanisms accounting for the therapeutic effect of allergy vaccines. Therefore, application of neoglycoconjugates via laser microporation represents a promising platform of highly efficient, safe, and painless vaccines for allergy treatment." (Machado et. al)